CA2308575A1 - Vecteurs d'expression inductible par hyperthermie utiles pour la therapie genique et procedes d'utilisation de ceux-ci - Google Patents

Vecteurs d'expression inductible par hyperthermie utiles pour la therapie genique et procedes d'utilisation de ceux-ci Download PDF

Info

Publication number
CA2308575A1
CA2308575A1 CA002308575A CA2308575A CA2308575A1 CA 2308575 A1 CA2308575 A1 CA 2308575A1 CA 002308575 A CA002308575 A CA 002308575A CA 2308575 A CA2308575 A CA 2308575A CA 2308575 A1 CA2308575 A1 CA 2308575A1
Authority
CA
Canada
Prior art keywords
promoter
expression
cell
expression construct
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002308575A
Other languages
English (en)
Inventor
Tom Tsang
Eugene Gerner
David T. Harris
Evan Hersh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arizona's Public Universities
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2308575A1 publication Critical patent/CA2308575A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des procédés et des compositions utiles pour exprimer des transgènes dans des cellules cibles. L'invention concerne des produits de recombinaison d'expression utilisant un système d'amplification inductible pour diriger l'expression d'un gène thérapeutique ou d'un autre gène intéressant dans des cellules hôtes de mammifère, ainsi que des procédés utiles à cet effet. L'expression inductible des transgènes à des concentrations élevées dans des conditions physiologiques est la conséquence d'une induction provoquée par des conditions d'hyperthermie par rapport à la température de base des cellules hôtes.
CA002308575A 1997-11-03 1998-11-03 Vecteurs d'expression inductible par hyperthermie utiles pour la therapie genique et procedes d'utilisation de ceux-ci Abandoned CA2308575A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6408897P 1997-11-03 1997-11-03
US60/064,088 1997-11-03
PCT/US1998/023387 WO1999023216A2 (fr) 1997-11-03 1998-11-03 Vecteurs d'expression inductible par hyperthermie utiles pour la therapie genique et procedes d'utilisation de ceux-ci

Publications (1)

Publication Number Publication Date
CA2308575A1 true CA2308575A1 (fr) 1999-05-14

Family

ID=22053477

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002308575A Abandoned CA2308575A1 (fr) 1997-11-03 1998-11-03 Vecteurs d'expression inductible par hyperthermie utiles pour la therapie genique et procedes d'utilisation de ceux-ci

Country Status (9)

Country Link
EP (1) EP1029041A2 (fr)
JP (1) JP2001521740A (fr)
KR (1) KR20010031762A (fr)
CN (1) CN1299411A (fr)
AU (1) AU1377299A (fr)
BR (1) BR9813917A (fr)
CA (1) CA2308575A1 (fr)
IL (1) IL135943A0 (fr)
WO (1) WO1999023216A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19951765A1 (de) * 1999-10-27 2001-05-03 Thomas Schweder Wirts-Vektor-Systeme zur Überproduktion von thermolabilen Enzymen psychrophiler Organismen
US6579522B1 (en) 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
US7285414B2 (en) 2000-09-26 2007-10-23 Emory University Viruses targeted to hypoxic cells and tissues
DE60137137D1 (de) * 2000-09-26 2009-02-05 Univ Emory Viren gegen hypoxische zellen und gewebe
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
PT2213730E (pt) 2002-06-18 2016-02-26 Eisai R&D Man Co Ltd Adipócitos de cultura primária para terapia génica
WO2004035082A2 (fr) * 2002-10-14 2004-04-29 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Proteines impliquees dans la regulation de l'homeostasie energetique
JP2008048601A (ja) * 2004-06-15 2008-03-06 Nippon Kosei Kagaku Kenkyusho:Kk 治療に有用な産物の生産法およびシステム
WO2006116789A2 (fr) * 2005-05-03 2006-11-09 Veterinärmedizinische Universität Wien Capsules permeables
NZ584848A (en) * 2007-09-28 2012-09-28 Intrexon Corp Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
CN103667345B (zh) * 2013-12-02 2015-10-28 东南大学 一种抗肿瘤基因磁性复合纳米颗粒及制备方法
WO2017133175A1 (fr) * 2016-02-04 2017-08-10 Nanjing Legend Biotech Co., Ltd. Cellules mammifères génétiquement modifiées pour thérapie anticancéreuse
CN108913661A (zh) * 2018-06-22 2018-11-30 安徽 一种人体研究用造血干细胞的制备和提取方法
CN114317588B (zh) * 2020-09-29 2023-06-27 中国农业科学院生物技术研究所 一种作物高温响应型基因组精准甲基化调控回路
IT202200000788A1 (it) * 2022-01-19 2023-07-19 Bruno Cell S R L Induzione sensibile alla temperatura del programma miogenico e/o adipogenico in cellule per la produzione di tessuto muscolare e/o adiposo
CN116536349B (zh) * 2023-05-22 2024-02-20 安徽农业大学 一种大豆GmMLP34基因在调控植物耐高温性上的应用
CN119327020A (zh) * 2024-12-18 2025-01-21 吉林大学 一种便携式双压电微泵作用的无痛注射装置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991770A (en) * 1974-01-24 1976-11-16 Leveen Harry H Method for treating benign and malignant tumors utilizing radio frequency, electromagnetic radiation
EP0299127A1 (fr) * 1987-07-16 1989-01-18 IntraCel Corporation Procédé pour exprimer des gènes recombinants, stimulés par une protéine activatrice, exprimée par induction
EP0455424A3 (en) * 1990-05-02 1992-04-29 Merck & Co. Inc. Mammalian inducible promoter cascade system
FR2717187B1 (fr) * 1994-03-10 1996-05-31 Transgene Sa Usage combiné de deux cassettes d'expression pour la production d'une protéine d'intérêt.

Also Published As

Publication number Publication date
JP2001521740A (ja) 2001-11-13
WO1999023216A2 (fr) 1999-05-14
KR20010031762A (ko) 2001-04-16
BR9813917A (pt) 2001-10-30
WO1999023216A3 (fr) 1999-08-05
AU1377299A (en) 1999-05-24
IL135943A0 (en) 2001-05-20
CN1299411A (zh) 2001-06-13
EP1029041A2 (fr) 2000-08-23

Similar Documents

Publication Publication Date Title
CA2308575A1 (fr) Vecteurs d'expression inductible par hyperthermie utiles pour la therapie genique et procedes d'utilisation de ceux-ci
EP0784693B1 (fr) Vecteurs viraux pour la therapie genique
US5674703A (en) Episomal vector systems and related methods
AU1755299A (en) Vector for tissue-specific replication and gene expression
WO1994012629A9 (fr) Vecteurs episomiques pour therapie genique
JPH10509880A (ja) 組織特異的複製のためのベクター
JP2004501650A (ja) 複製欠損アデノウイルスｔｎｆベクター
JP2002506651A (ja) 多重遺伝子ベクター
US6709858B1 (en) Hyperthermic inducible expression vectors for gene therapy and methods of use thereof
US20070244064A1 (en) Methods and compositions to induce antitumor response
US7056897B2 (en) Inducible expression vectors and methods of use thereof
ES2268695T3 (es) Adenovirus recombinantes defectivos con una gen iva2 inactivado.
US6451579B1 (en) Regulated expression of recombinant proteins using RNA viruses
Tomita et al. Gene therapy with transcription factor decoy oligonucleotides as a potential treatment for cardiovascular diseases
Kouraklis Gene therapy for cancer
Engelhard Gene therapy for brain tumors: the fundamentals
US7098191B2 (en) Hyperthermic inducible expression vectors for gene therapy and methods of use thereof
WO1997016547A1 (fr) VECTEURS D'EXPRESSION ADENOVIRAUX ANTISENS DU K-ras ET LEUR APPLICATION EN THERAPIE ANTICANCEREUSE
WO2000022124A2 (fr) Procedes et compositions permettant d'induire une reponse antitumorale
Palapattu et al. GENE THERAPY FOR PROSTATE CANCER: New Perspectives on an Old Problem
MXPA00004293A (en) Hyperthermic inducible expression vectors for gene therapy and methods of use thereof
Clayman Gene therapy for head and neck cancer
JPH10127287A (ja) 生体内でヒト遺伝子を導入するための新規アデノウィルス・ベクター
JP7406263B2 (ja) 改変アデノウイルス及びこれを含む医薬
US5863794A (en) SV40 viral vectors for targeted integration into cells

Legal Events

Date Code Title Description
FZDE Discontinued